Qaasid News

Download Our App

Category: 3. Business

  • Immunotherapy Advances in SCLC Highlight Promise, Limitations, and Biomarker Needs

    Immunotherapy Advances in SCLC Highlight Promise, Limitations, and Biomarker Needs

    The current state of the small cell lung cancer (SCLC) treatment paradigm rests on meaningful efficacy gains with immunotherapy approaches, although there remains an urgent need to identify predictive biomarkers to better tailor therapy and explore the utility of agents beyond immune checkpoint inhibitors (ICIs), according to Christine Hann, MD, PhD.1

    In a presentation at the 20th Annual New York Lung Cancers Symposium®, Hann highlighted how recently presented SCLC data inform treatment decision-making across the limited-stage and extensive-stage settings. She explored various findings with consolidation durvalumab (Imfinzi), ups and downs regarding atezolizumab (Tecentriq) data, and the importance of identifying novel biomarkers to further individualize SCLC management.

    Hann is an associate professor of oncology at the Johns Hopkins School of Medicine and a physician at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland.

    What are some of the most recent advances and setbacks in therapeutic development for LS-SCLC?

    The ADRIATIC Trial

    Hann began by discussing the significance of data that have been reported from the phase 3 ADRIATIC trial (NCT03703297), which is investigating durvalumab as consolidation therapy in patients with stage III inoperable limited-stage SCLC (LS-SCLC). Data presented at the 2024 ASCO Annual Meeting showed that patients who received durvalumab monotherapy (n = 264) experienced a median progression-free survival (PFS) of 16.6 months (95% CI, 10.2-28.2) vs 9.2 months (95% CI, 7.4-12.9) with placebo (n = 266; HR, 0.76; 95% CI, 0.61-0.95; P = .0161).2 The median overall survival (OS) was 55.9 months (95% CI, 37.3-not evaluable) vs 33.4 months (95% CI, 25.5-39.9) with placebo (HR, 0.73; 95% CI, 0.57-0.93; P = .0104).

    Hann also homed in on the safety findings from ADRIATIC, which showed that patients in the durvalumab arm received a median of 9.0 doses (range, 1-26) of the treatment. In this arm, the rate of any-grade all-cause adverse effects (AEs) was 94.3%, and the rate of any-grade immune-mediated AEs was 32.1%. Notably, any-grade radiation pneumonitis was seen in 22.9% of patients in this arm.

    “Notable findings [from subgroup analyses] were that [patients who received] once-daily and twice-daily [dosing] both seem to benefit [from durvalumab],” Hann said, adding that “These are trends, not absolutes.”

    Based on these data, in December 2024, the FDA approved durvalumab for the treatment of adult patients with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.3

    Hann added that data from the durvalumab/tremelimumab of ADRIATIC are still awaited.

    The NRG-LU005 Study

    Hann pivoted to provide context about findings from the phase 3 NRG-LU005 trial (NCT03811002), which investigated the use of concurrent atezolizumab and chemoradiotherapy in patients with limited-stage disease. Data from the second planned interim analysis showed no PFS or OS improvements with the concurrent administration of atezolizumab and standard-of-care (SOC) chemoradiotherapy vs chemoradiotherapy alone.4

    “This was reminiscent of data that we’ve seen in [the phase 3] PACIFIC-2 [trial (NCT03519971)],” Hann explained. “It seems like immunotherapy given concurrently with chemoradiation offers no benefit.”

    Notably, data from the final analysis of PACIFIC-2 showed that concurrent administration of durvalumab and SOC chemoradiotherapy followed by consolidation durvalumab (n = 219) did not result in a significant PFS benefit vs placebo plus SOC chemoradiotherapy (n = 109; HR, 0.85; 95% CI, 0.65-1.12; P = .247).5

    The ACHILES Trial

    Additional data with atezolizumab in the context of chemoradiotherapy in LS-SCLC came from the phase 2 ACHILES trial (NCT03540420) and were presented at the 2025 ASCO Annual Meeting. In this study, patients who received consolidation atezolizumab after chemoradiotherapy (n = 85) had a median OS of 43.4 months (95% CI, 25.1-51.2); the median OS was 38.8 months (95% CI, 25.8-57.6) among patients who underwent observation following chemoradiotherapy (n = 85). Although there was a numerical improvement in OS in the atezolizumab arm, this did not meet statistical significance (HR, 1.14; 95% CI, 0.76-1.71; P = .53).6

    “It’s notable that the observation arm performed better than [in] other studies,” Hann stated. “For immunotherapy in LS-SCLC, the [optimal population] are patients with at least stable disease after chemoradiation, [and the ideal treatment and duration are] up to 2 years of durvalumab consolidation, which improves PFS and OS. Toxicity is manageable. Benefits [were] observed over the different subgroups, so [we should be] comfortable [using] once-daily or twice-daily radiation and either platinum agent.”

    Hann summarized that, so far, clinical trial data have not shown a benefit with atezolizumab given concurrently with chemoradiation as maintenance or consolidation therapy. However, she explained that data from ongoing phase 3 trials with immunotherapy agents in LS-SCLC may add nuance to the question of the optimal role for immunotherapy-based combinations, in terms of efficacy as well as safety.

    What do clinical data indicate about the role of immunotherapy in patients with ES-SCLC?

    Turning to paradigm-defining data in extensive-stage SCLC (ES-SCLC), Hann focused on the benefits and limitations seen with the use of first-line immunotherapy in the phase 3 Impower133 (NCT02763579) and CASPIAN (NCT03043872) trials.

    “The trials were designed slightly differently, but the outcomes were similar,” she reported. “There is a small population [of patients who] are doing well [with frontline immunotherapy]. In the rest, we could probably use additional therapy. [Across clinical studies], whether [patients received] PD-1 or PD-L1 [inhibition plus platinum/etoposide], there seems to be consistent benefit [in terms of an] improvement in median OS.”

    She then summarized the results of several combination studies in the ES-SCLC setting, concluding that most did not show efficacy benefits with immunotherapy combination regimens vs single-agent immunotherapy. However, she spotlighted the biomarker-based phase 2 SWOG S1929 trial (NCT04334941), which evaluated maintenance atezolizumab alone vs in combination with talazoparib in patients with SLFN11-positive ES-SCLC. In this trial, the median PFS was 4.2 months (80% CI, 2.8-4.7) in the talazoparib arm (n = 54) vs 2.8 months (80% CI, 2.0-2.9) in the atezolizumab monotherapy arm (n = 52; HR, 0.70; 80% CI, 0.52-0.94; 1-sided log-rank stratified P = .056).7

    “[It is] important to show that a biomarker-based study could be conducted in SCLC,” she noted.

    Furthermore, Hann highlighted data from the phase 3 IMforte trial (NCT05091567) of first-line maintenance therapy with lurbinectedin (Zepzelca) plus atezolizumab that were presented at ASCO 2025. In this trial, patients with ES-SCLC who received the combination (n = 242) achieved a median PFS by independent review facility of 5.4 months (95% CI, 4.2-5.8) vs 2.1 months (95% CI, 1.6-2.7) with atezolizumab monotherapy (n = 241; stratified HR, 0.54; 95% CI, 0.43-0.67; 2-sided P< .0001).8 The median OS was 13.2 months (95% CI, 11.9-16.4) with the combination vs 10.6 months (95% CI, 9.5-12.2) with atezolizumab alone (stratified HR, 0.73; 95% CI, 0.57-0.95; 2-sided P = .0174).

    Notably, these data supported the October 2025 FDA approval of lurbinectedin plus atezolizumab or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as maintenance therapy for adult patients with ES-SCLC whose disease has not progressed after frontline induction therapy with atezolizumab or atezolizumab and hyaluronidase, carboplatin, and etoposide.9

    “With these data, etoposide plus a PD-L1 inhibitor is standard frontline therapy,” Hann reported. “Lurbinectedin offers PFS and OS benefit when added to maintenance atezolizumab as an option for, I say, select [patients with SCLC]. They have to be pretty fit and technically [have] no brain metastases at presentation. Toxicities are predictable but can be significant.”

    What may be the future role of biomarkers in SCLC?

    Hann concluded her presentation by emphasizing the importance of finding predictive biomarkers to further refine the role of immunotherapy. Questions remain as to which patient populations would benefit most from immunotherapy as monotherapy vs part of combination regimens. Hann also noted the uncertainty around optimal treatment strategies for patients with small cell transformation from EGFR-mutant adenocarcinoma, acknowledging that although early data suggest that ICIs might not be the most effective in this population, other types of immunotherapies might provide better outcomes. She also emphasized the importance of developing therapies that are more effective than chemotherapy for patients who are not eligible to receive ICIs, including those with active autoimmune conditions, those who have undergone transplant, and those who have paraneoplastic syndrome.

    References

    1. Hann CL. Immunotherapy in SCLC: when, what, and how much? Presented at: 20th Annual New York Lung Cancers Symposium; November 15, 2025; New York, New York.
    2. Spigel DR, Cheng Y, Cho BC, et al. ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol. 2024;42(suppl 17):LBA5. doi:10.1200/JCO.2024.42.17_suppl.LBA5
    3. FDA approves durvalumab for limited-stage small cell lung cancer. FDA. December 4, 2024. Accessed November 15, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer
    4. NRG Oncology trial implies the addition of atezolizumab concurrently to standard of care does not improve survival in limited-stage small cell lung cancer. News release. NRG Oncology. September 30, 2024. Accessed November 15, 2025. https://www.nrgoncology.org/Home/News/Post/nrg-oncology-trial-implies-the-addition-of-atezolizumab-concurrently-to-standard-of-care-does-not-improve-survival-in-limited-stage-small-cell-lung-cancer
    5. Bradley JD, Sugawara S, Lee KHH, et al. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. ESMO Open. 2024;9(suppl 3):102986. doi:10.1016/j.esmoop.2024.102986
    6. Gronberg BH, Aanerud M, Dumoulin DW, et al. Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). J Clin Oncol. 2025;43(suppl 17):LBA8005. doi:10.1200/JCO.2025.43.17_suppl.LBA8005
    7. Karim NFA, Miao J, Reckamp KL, et al. SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2023;41(suppl 16):8504. doi:10.1200/JCO.2023.41.16_suppl.8504
    8. Paz-Ares L, Borghaei H, Liu SV, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial. J Clin Oncol. 2025;43(suppl 16):8006. doi:10.1200/JCO.2025.43.16_suppl.8006
    9. FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer. FDA. October 2, 2025. Accessed November 15, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive?utm_medium=email&utm_source=govdelivery

    Continue Reading

  • A Look at Ag Growth International (TSX:AFN) Valuation Following New High-Capacity Grain Conveyor Launches

    A Look at Ag Growth International (TSX:AFN) Valuation Following New High-Capacity Grain Conveyor Launches

    Ag Growth International (TSX:AFN) just unveiled two new high-capacity grain conveyors, the FX4 SP and FX4 18S. This expands its lineup with equipment focused on mobility, efficiency, and durability for today’s farming operations.

    See our latest analysis for Ag Growth International.

    All eyes have been on Ag Growth International after the release of its upgraded conveyors, but the excitement has not stopped the share price from tumbling. Most recently, the company experienced a one-day share price return of -40.15% and a one-year total shareholder return of -61.79%. Even with ongoing product innovation, momentum has faded significantly, reminding investors that near-term risks remain key to the broader story.

    If you’re looking beyond single stocks for your next idea, now is a prime moment to expand your search and discover fast growing stocks with high insider ownership

    With shares down sharply despite these high-profile launches, the key question is whether Ag Growth International is now trading below its true value or if investors are right to be cautious about future growth prospects. Is this a buying opportunity, or is the market already pricing in all that lies ahead?

    The most widely followed narrative indicates that Ag Growth International’s fair value is far above its last close. With the stock recently trading at CA$19.42 and the narrative’s fair value at CA$53.38, there is a dramatic disconnect between the current price and long-term projections. This sets the stage for a significant debate over what is driving analyst conviction for future upside.

    Operational improvements, financial discipline, and innovation are enhancing margins, boosting cash flow, and positioning for long-term market leadership.

    Read the complete narrative.

    Curious why this price target is so aggressive? The narrative hinges on forecasts for a rapid margin turnaround powered by new growth engines. But what is the boldest assumption underpinning this outlook? Find out which key transformation is expected to propel both profit margins and earnings to levels that could drastically reshape the stock’s valuation story.

    Result: Fair Value of $53.38 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent weakness in the Farm segment or delays in reducing net debt could quickly undermine the positive outlook and weigh on future performance.

    Find out about the key risks to this Ag Growth International narrative.

    If you’re ready to challenge the consensus or want to dig into the numbers yourself, it only takes a few minutes to build your own perspective. Do it your way

    A great starting point for your Ag Growth International research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

    Don’t let smart opportunities pass you by. Give yourself an edge with innovative investment ideas that could take your portfolio to the next level.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include AFN.TO.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • How Subdued Guidance and Inventory Pressures Could Shape Microchip Technology’s (MCHP) Earnings Trajectory

    How Subdued Guidance and Inventory Pressures Could Shape Microchip Technology’s (MCHP) Earnings Trajectory

    • Earlier this month, Microchip Technology reported quarterly earnings showing a year-on-year drop in both revenue and net income, alongside a cautious forward guidance attributed to inventory correction pressures and a softer demand environment.

    • An important development for the company is the launch of the LAN866x series, which aims to ease network integration and reduce costs in automotive Ethernet applications by enabling software-less, efficient endpoint connectivity.

    • We’ll explore how Microchip’s subdued guidance and continued inventory challenges may influence its outlook for earnings and margin recovery.

    AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

    To own shares of Microchip Technology today, you need confidence in its ability to recover from ongoing inventory corrections and margin pressure while capitalizing on secular trends like increased vehicle electrification and edge AI. While the new LAN866x series targets growth in automotive Ethernet, the bigger picture remains driven by managing excess inventory and restoring earnings momentum. The impact of this launch on short-term catalysts, such as margin recovery, is not material, as inventory normalization is still the central near-term challenge for the business.

    Among recent announcements, the Ceva partnership to bring advanced Neural Processing Units into Microchip products stands out for its relevance to future growth catalysts. By embedding scalable AI directly in its compute, communication, and security solutions, Microchip aims to expand its reach in next-generation edge and data center markets, key drivers highlighted in the recovery narrative, beyond automotive network innovation.

    However, investors should also consider that, unlike the upside from new product cycles, ongoing inventory write-offs and factory underutilization charges remain critical headwinds that…

    Read the full narrative on Microchip Technology (it’s free!)

    Microchip Technology’s outlook anticipates $6.6 billion in revenue and $1.4 billion in earnings by 2028. Achieving these targets implies an annual revenue growth rate of 15.9% and a $1.58 billion increase in earnings from the current level of -$178.4 million.

    Uncover how Microchip Technology’s forecasts yield a $74.68 fair value, a 40% upside to its current price.

    MCHP Community Fair Values as at Nov 2025

    Six individual fair value estimates from the Simply Wall St Community range between US$22.39 and US$90 per share. Opinions vary, especially given persistent inventory challenges and their broader effects on profitability, so take the time to compare multiple views for a fuller picture.

    Explore 6 other fair value estimates on Microchip Technology – why the stock might be worth less than half the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include MCHP.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Exploring Current Valuation After Recent Share Price Surge

    Exploring Current Valuation After Recent Share Price Surge

    Seagate Technology Holdings (STX) has caught investor attention as its stock makes notable moves this month. With the tech sector in flux, Seagate’s recent price performance offers a starting point for those eyeing value and growth potential.

    See our latest analysis for Seagate Technology Holdings.

    Seagate’s share price is up a jaw-dropping 198.89% year-to-date, with trend-defining gains over the past quarter and a 173.25% total shareholder return in the past year. This kind of momentum signals growing optimism from investors that the company’s turnaround is the real deal, especially as short-term swings work themselves out against the backdrop of dramatic long-term outperformance.

    If you’re looking for the next big opportunity in tech, it makes sense to check out the latest movers and fast-risers. See the full list for free with our See the full list for free..

    But given such rapid gains, is Seagate truly undervalued based on its fundamentals, or have expectations already pushed the price to reflect every bit of its future growth? Is there still a buying opportunity, or has the market already priced in what comes next?

    Seagate’s most widely followed narrative suggests its fair value stands well above the last close price. This sets up a debate about whether strong profitability and innovation can power further upside.

    Seagate is ramping up its HAMR-based Mozaic drives, which represent a technological breakthrough. The transition to these drives is expected to lead to sustained and profitable growth, impacting both revenue and net margins positively.

    Read the complete narrative.

    Want to know what’s fueling this bullish price target? The narrative builds its case on industry-defining innovation, with underlying projections that might challenge even the most optimistic expectations. See the full forecast breakdown and get the details that are moving the numbers.

    Result: Fair Value of $277.25 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, unexpected shifts in trade policy or renewed industry competition could quickly challenge Seagate’s upbeat outlook and current valuation narrative.

    Find out about the key risks to this Seagate Technology Holdings narrative.

    If you have a different take or want to dive into the numbers yourself, it’s never been easier to put together your own story. Discover insights in just a few minutes and Do it your way.

    A great starting point for your Seagate Technology Holdings research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

    Don’t let opportunity pass you by when there are standout investment themes on Simply Wall Street’s Screener. Make your next smart move today and you might just spot your new favorite stock.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include STX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Adidas Early Black Friday Deal: Classic Sambas Now $70

    Adidas Early Black Friday Deal: Classic Sambas Now $70

    Adidas is kicking off Black Friday with an early sale that includes must-see deals on a wide range of Adidas Sambas and more Adidas shoe styles.

    The Adidas early Black Friday sale gives adiClub members first access to discounts of up to 60% off. You do need to join the adiClub to unlock these deals, but it’s free to join and you will get access to reduced prices on Sambas, Adidas Gazelles, Adidas Handball Spezials, and much more before everyone else.

    There’s more than just footwear on sale. You can shop discounts on top styles, including matching sets, hoodies and sweatshirts, jackets and coats, fitness dresses, and more.

    You’ll want to hurry if you want access to this early sale. It ends November 19. Snag your new pair of Adidas Sambas for $70 below!

    Continue Reading

  • Why Sanara MedTech (SMTI) Is Refocusing After Discontinuing THP Division and Reporting Quarterly Losses

    Why Sanara MedTech (SMTI) Is Refocusing After Discontinuing THP Division and Reporting Quarterly Losses

    • Sanara MedTech announced the discontinuation of its Tissue Health Plus (THP) division and reported third-quarter earnings, with sales reaching US$26.33 million and a net loss of US$30.41 million for the period ended September 30, 2025.

    • This move marks a business realignment to concentrate on the core surgical segment, with management expecting THP wind-down costs to conclude by the end of 2025 and further resource shifts to support main operations.

    • We’ll explore how the decision to exit THP and focus on core surgical products influences Sanara MedTech’s investment outlook.

    AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

    To be a Sanara MedTech shareholder, you need to believe in the potential of its core surgical segment to drive future growth and profitability, especially as the company pivots away from digital health. The decision to discontinue the THP division directly addresses one of the short-term risks, persistent net losses and resource drag, while sharpening focus on the surgical business, which remains the primary catalyst for near-term improvement. The move does not materially change competitive or market risks, but it may impact resource allocation and operational priorities in the coming quarters. Among recent announcements, the company’s accelerated growth in its distributor and healthcare facility network is particularly relevant. This expanded reach could support higher sales volumes for Sanara’s proprietary surgical products and help offset both the transitional costs of winding down THP and the ongoing pressure from limited portfolio diversification. But on the flip side, investors should be aware that Sanara’s continued heavy focus on a narrow range of surgical wound care products means that…

    Read the full narrative on Sanara MedTech (it’s free!)

    Sanara MedTech’s outlook anticipates $144.9 million in revenue and $1.9 million in earnings by 2028. This scenario is based on a 14.2% annual revenue growth rate and an $11.8 million increase in earnings from the current -$9.9 million.

    Uncover how Sanara MedTech’s forecasts yield a $41.00 fair value, a 90% upside to its current price.

    SMTI Earnings & Revenue Growth as at Nov 2025

    Three distinct fair value estimates from the Simply Wall St Community fall between US$18.41 and US$41. With investors split on valuation, pay close attention to ongoing net losses and how business realignment could affect future earnings.

    Explore 3 other fair value estimates on Sanara MedTech – why the stock might be worth 15% less than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    • A great starting point for your Sanara MedTech research is our analysis highlighting 1 key reward that could impact your investment decision.

    • Our free Sanara MedTech research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Sanara MedTech’s overall financial health at a glance.

    Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SMTI.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Why Fluence Energy (FLNC) Is Down 13.9% After Lowered 2025 Guidance on US Factory Delays

    Why Fluence Energy (FLNC) Is Down 13.9% After Lowered 2025 Guidance on US Factory Delays

    • Earlier this week, Fluence Energy reported it expects fiscal year 2025 revenues to meet only the lower end of its prior guidance, citing slower-than-expected production ramp-up at new US manufacturing facilities and resulting delays set to affect fiscal year 2026.

    • An important development is the company’s projection that these US sites will reach full capacity by year-end, which may enhance future delivery capabilities and strengthen Fluence’s domestic content position for its energy storage products.

    • We’ll examine how the manufacturing delays and revised guidance may reshape Fluence Energy’s investment narrative and future growth outlook.

    Uncover the next big thing with financially sound penny stocks that balance risk and reward.

    To be a shareholder in Fluence Energy, you need confidence in the decades-long shift toward grid-scale battery storage and the company’s ability to scale domestic production to capitalize on rising electrification and clean energy demand. This week’s lowered revenue guidance linked to US facility production delays directly impacts the timeline of the company’s most important short-term catalyst, achieving reliable, resilient US-based supply, and magnifies the biggest current risk: further disruption from supply chain or policy uncertainty. While management reaffirms capacity ramp by year-end, the delay is meaningful for near-term delivery expectations.

    The September 2025 announcement of Fluence’s first shipment of lithium-ion battery systems using U.S.-made components directly ties into the company’s pivot to domestic content, which remains central to its eligibility for incentives and its cost competitiveness. This milestone, once full plant utilization is realized, is critical for unlocking deferred contract revenue and reducing risk exposure to ongoing tariff volatility. However, for investors, an essential consideration remains…

    Read the full narrative on Fluence Energy (it’s free!)

    Fluence Energy’s narrative projects $4.2 billion in revenue and $97.9 million in earnings by 2028. This requires 19.5% yearly revenue growth and a $116.3 million increase in earnings from the current level of $-18.4 million.

    Uncover how Fluence Energy’s forecasts yield a $10.53 fair value, a 41% downside to its current price.

    FLNC Community Fair Values as at Nov 2025

    Seven individual fair value estimates from the Simply Wall St Community for Fluence Energy span from US$10.53 to US$25.75 per share, showing wide disagreement in expectations. With production delays now affecting near-term revenue and profit timing, your view on supply chain execution could make all the difference, see how others approach the stock and weigh up the various arguments for yourself.

    Explore 7 other fair value estimates on Fluence Energy – why the stock might be worth 41% less than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include FLNC.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Evaluating Prada’s Share Price After a 25% Decline and Recent Sector Interest

    Evaluating Prada’s Share Price After a 25% Decline and Recent Sector Interest

    • Thinking about whether Prada’s current share price is a bargain? If you have ever wondered how much quality you are really getting for your money, you are in the right place.

    • Prada’s stock has seen a fair share of swings lately, rising 5.8% in the past week and 2.7% for the month. However, it is still down 25.3% year to date.

    • These moves have been accompanied by notable headlines, including renewed interest from luxury sector investors and speculation about evolving consumer demand in key global markets. Industry news has highlighted shifts in both the luxury retail landscape and Prada’s ability to adapt. Both of these factors help to explain recent market sentiment.

    • When we run Prada through our six standard valuation checks, it scores a 2 out of 6 for being undervalued. We will break down what that means for investors using familiar valuation tools, and show you an even more insightful way to think about value by the end of this article.

    Prada scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future cash flows and discounting them to present-day value. This approach aims to capture how much future profits are really worth today, adjusting for time and risk.

    For Prada, the latest data shows that its Free Cash Flow over the last twelve months was €933.8 Million. Analyst estimates suggest that, by the end of 2027, Prada’s Free Cash Flow will reach about €1.39 Billion. Simply Wall St then extends these projections for the next decade. By 2035, extrapolated estimates put Free Cash Flow at nearly €1.9 Billion. These medium-to-long-term projections form the basis for the valuation analysis.

    Running this through the DCF model, Prada’s estimated intrinsic value per share comes in at HK$53.58. This suggests the stock is currently trading at a 12.4% discount relative to its fair value. In other words, the market price is below what the cash flows imply it should be.

    Result: UNDERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests Prada is undervalued by 12.4%. Track this in your watchlist or portfolio, or discover 879 more undervalued stocks based on cash flows.

    1913 Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Prada.

    The Price-to-Earnings (PE) ratio is widely used to value established, profitable companies like Prada. It tells investors how much they are paying for each unit of current earnings, and is especially helpful for comparing companies of similar size or within the same sector.

    Continue Reading

  • Assessing Valuation After New AI Workforce and Cloud Transformation Forecasts

    Assessing Valuation After New AI Workforce and Cloud Transformation Forecasts

    Gartner (NYSE:IT) has sparked conversation across enterprise circles after releasing new forecasts about artificial intelligence’s sweeping impact on the workforce. The company’s latest research is drawing interest for its clear look at how AI could reshape job roles, IT work, and digital infrastructure strategies.

    See our latest analysis for Gartner.

    This wave of AI research comes on the heels of a busy period for Gartner, with the company recently announcing an $800 million senior notes offering and updating its full-year revenue outlook upward. In the past year, however, Gartner’s share price return has slumped by 52.2%, and the total shareholder return sits even lower at -55.8%. This underscores fading momentum despite strategic moves and robust thought leadership. Long-term holders have still enjoyed a positive 51.4% total return over five years, but recent performance highlights the increased uncertainty and risk perception reflected in the company’s valuation.

    If Gartner’s shifting trajectory has you rethinking your next move, this could be the perfect moment to broaden your search and discover fast growing stocks with high insider ownership

    With a year of falling returns but a solid history and signs of healthy growth, the question now is whether Gartner’s recent setbacks are masking an undervalued opportunity or if the market has already taken its future prospects into account.

    Compared to Gartner’s last close price of $231.03, the most popular narrative’s fair value estimate of $285.45 reflects a significant gap. This discrepancy highlights what analysts believe are the drivers behind Gartner’s true worth.

    *The rapid increase in enterprise adoption of AI, digital transformation, cybersecurity, and complex IT strategies is driving rising client demand for Gartner’s proprietary insights across multiple functions and industries. This supports potential long-term revenue acceleration as enterprises seek trusted guidance for mission-critical initiatives.*

    Read the complete narrative.

    Want to know what’s powering this bold upside? The market’s current view does not account for a future shaped by transformative digital investments and a strategic change in Gartner’s client relationships. The real engine behind the narrative valuation relies on shifting earnings, margins, and sharp revenue expectations. Which forecasted trend tips the scale? Crack open the full story to see the hidden math that justifies this fair value call.

    Result: Fair Value of $285.45 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, ongoing cost-cutting by clients and the rapid rise of open-source AI tools could put pressure on Gartner’s recurring revenues and present challenges to the long-term upside case.

    Find out about the key risks to this Gartner narrative.

    Feel like a different story is unfolding, or want to examine the numbers on your own terms? You can dive in and craft your own view in just a few minutes: Do it your way

    A great starting point for your Gartner research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Smart investors never settle for what’s familiar. Expand your opportunities and get ahead of the next trend by tapping into curated lists of companies reshaping the market.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include IT.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Ethereum Holders Are More Willing Than Bitcoin Investors to Part With Coins: Glassnode

    Ethereum Holders Are More Willing Than Bitcoin Investors to Part With Coins: Glassnode

    Bitcoin holders are still the true “diamond hands” investors compared to Ethereum buyers, according to a new report, with the latter coins being moved and spent far more than the original so-called digital gold.

    Blockchain data firm Glassnode said in a new report—citing data collected before this week’s crypto crash—that BTC moves less frequently than ETH, behaving more like a “digital savings asset.” 

    ETH moves far more as it functions as “digital oil,” which is both stockpiled and actively used as network fuel and collateral. 

    “Bitcoin behaves like the digital savings asset it was designed to be, in that coins are largely hoarded, turnover is low, and recent behavior shows that more supply is migrating into long-term hold wrappers rather than sitting on exchanges,” the report said. 

    “Ethereum’s behavior also reflects the inherent properties of a high transaction smart contract platform,” it added, “with a large anchored base from native staking, with the addition of recent market forces adding an investor component through ETFs.”

    The report goes on to note why: Ethereum’s use in smart contracts, which hold the code that powers a wide array of decentralized applications, DeFi platforms, and tokenized assets.

    As Glassnode notes, “ETH’s long-term holders are mobilizing their old coins at a rate that’s 3x faster than BTC’s long-term holders, signaling ETH’s long-term holders are more willing to part with their coins, pointing to utility-driven behavior.”

    Ethereum powers crypto applications, ranging from stablecoins to decentralized finance exchanges. To make transactions sending digital dollars or to swap tokens on a decentralized crypto exchange, users need to pay gas fees in ETH. 

    It is because of the Ethereum network’s use cases that, despite the approval of exchange-traded funds now trading on traditional stock exchanges, ETH still works less like a store-of-value asset compared to BTC—and that the coins are less dormant. 

    Bitcoin, Ethereum ETFs Shed Over $1 Billion in Assets as XRP Fund Soars

    Still, ETH still can have store-of-value use cases, Glassnode noted, explaining that “one out of every four ETH is locked in native staking and ETFs.” 

    Ethereum’s price recently stood at nearly $3,208, down 4.5% over the past week. The coin was slow in reaching an all-time high but finally did so in August, breaking a nearly four-year-old record. It has traded well below that level—$4,946—in recent weeks. 

    Bitcoin was recently trading at $95,992, falling by nearly 6% over the past seven days. The coin’s all-time high stands at $126,088, touched in October.

    Continue Reading